IC
ACRS icon

Innealta Capital’s Aclaris Therapeutics ACRS Stock Holding History

Innealta Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-56
Closed -$62 – 175
2024
Q2 		$62 Buy
+56
New +$66 ﹤0.01% 1732

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Innealta Capital's ACRS Position: Q3 2024 in Review

Innealta Capital sold out of Aclaris Therapeutics (ACRS) in Q3 2024, closing a stake of 56 shares — an estimated $62 sold.

Innealta Capital first reported a position in ACRS in Q2 2024 and held it in 1 quarter. The position peaked at $62 in Q2 2024. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

  • Innealta Capital reported no remaining Aclaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 56 Aclaris Therapeutics shares in Q3 2024, an estimated $62.
  • Innealta Capital first reported a position in Aclaris Therapeutics in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Aclaris Therapeutics position peaked at $62 in Q2 2024.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.